ArticleiScience2025
Catalyzing early ovarian cancer detection: Platelet RNA-based precision screening.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of ovarian cancer is crucial for successful treatment, yet most cases are diagnosed at advanced stages due to a lack of effective screening. Recent advancements in RNA technology from platelets aid in early tumor detection. Here, we proposed our two-step method for assessing the existence of pelvic mass either located at ovaries or uterus with more than 99% specificity by utilizing exon-exon junction features with a sampling invariant normalization technique; then next our model finds the malignancy of detected mass with more than 99% negative predictive value for ovarian cancer to practically assist clinicians' further investigation via combined features of exon-exon junctions, and hematology parameters. We diverged from traditional methods by employing intron-spanning reads (ISR) counts rather than gene expression levels to use splice junctions as features in our models. If integrated with current screening methods, our algorithm holds promise for identifying ovarian or endometrial cancer in its early stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.